In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 285

TitleTypeExpected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Technology appraisal guidanceTBC
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]Technology appraisal guidanceTBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232Technology appraisal guidanceTBC
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]Technology appraisal guidance
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354Technology appraisal guidanceTBC
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247]Technology appraisal guidanceTBC
ALXN1840 for treating Wilson disease TS ID 9950Technology appraisal guidanceTBC
Alzheimer's disease (early) - gantenerumab [ID6142]Technology appraisal guidanceTBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]Technology appraisal guidance
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]Technology appraisal guidance
Amyotrophic lateral sclerosis - SAR443820 [ID6386]Technology appraisal guidanceTBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidanceTBC
Asunercept for treating glioblastoma [1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Technology appraisal guidanceTBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]Technology appraisal guidance
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Technology appraisal guidanceTBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]Technology appraisal guidanceTBC
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]Technology appraisal guidanceTBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All